Acumen Pharmaceuticals, Inc.

Acumen ended Q2 2026 with $110.2 million in cash and marketable securities, expected to fund current clinical and operational activities into early 2027. R&D expense was $27.8 million, down year over year primarily due to lower manufacturing/materials costs and CRO costs. G&A expense was $4.7 million, roughly flat versus the prior-year period. That produced a loss from operations of $32.6 million and a net loss of $32.7 million. Management reiterated that ALTITUDE-AD topline results for sabirnetug are expected late this year, and the readout is expected to include the primary endpoint iADRS, CDR-SB, safety including ARIA, and fluid and imaging biomarkers.

Dan O’Connell said the company is focused on disciplined execution ahead of the ALTITUDE-AD Phase II readout, which he called a potentially important efficacy event for the Alzheimer's field. He repeatedly framed sabirnetug as a test of the company's central thesis that selectively targeting synaptotoxic amyloid-beta oligomers could offer a differentiated approach. He also highlighted continued momentum in the EBD program, saying the two nominated candidates broaden optionality and that the program’s brain-penetration data exceeded expectations. His tone was confident and anticipatory, with several references to a “landmark catalyst” later this year.

Matt Zuga said the company had $110.2 million in cash and marketable securities at quarter-end, which should support operations into early 2027. He reported R&D expense of $27.8 million, down from the prior year mainly because manufacturing/materials and CRO costs decreased as the trial nears completion. G&A was $4.7 million and roughly flat year over year. He also reported a $32.6 million operating loss and a $32.7 million net loss for the quarter, while emphasizing continued investment toward the Phase II readout and the EBD program.

Analysts focused on how sabirnetug differs from other oligomer-targeting antibodies, the statistical framework of the two-dose ALTITUDE-AD design, and what steps are being taken now to compress the timeline into Phase III if Phase II is positive. Management declined to disclose detailed powering assumptions but said both doses have shown target engagement and could emerge as efficacious. They also said some Phase III preparatory work is already underway, though formal regulatory interactions on the next study design are not yet. Questions on biomarkers and digital twins were answered with a “measure now, learn later” approach: p-tau217 is in screening and will be an outcome measure, MTBR-tau243 and other emerging biomarkers may be analyzed post hoc, and Unlearn.AI digital twins are being used exploratorily to evaluate future utility.